Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis
Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis
复制标题
DOI：
10.1212/01.wnl.0000254620.45529.97
复制
发表时间：
2007-02-20
期刊：
影响因子：
9.9
通讯作者：
Saruhan-Direskeneli, G.
中科院分区：
文献类型：
--
作者：
Deymeer, F.;Gungor-Tuncer, O.;Saruhan-Direskeneli, G.
我们比较了65例抗乙酰胆碱受体（AChR）阴性的重症肌无力（MG）患者，包括32例抗肌肉特异性酪氨酸激酶（MuSK）阳性（49%）和33例抗MuSK阴性（血清阴性）（51%）患者，与161例抗AChR阳性的MG患者。抗MuSK阳性组的延髓受累和呼吸危象发生率较高。血清阴性组介于抗MuSK阳性组和抗AChR阳性组之间，就疾病的严重程度而言，更接近后者。在随访结束时，抗MuSK阳性患者的结果与抗AChR阳性患者的结果没有差异，尽管他们的维持皮质类固醇剂量较高。血清学阴性患者的预后优于其他两组。
We compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, including 32 anti-muscle-specific tyrosine kinase (MuSK)-positive (49%) and 33 anti-MuSK-negative (seronegative) (51%) patients, with 161 anti-AChR-positive MG patients. The anti-MuSK-positive group had a higher frequency of bulbar involvement and respiratory crises. The seronegative group was in between the anti-MuSK positive and the anti-AChR positive groups, being closer to the latter, with regard to the severity of the disease. At the end of follow-up, the outcome of the anti-MuSK-positive patients was not different from that of the anti-AChR-positive patients, although their maintenance corticosteroid dose was higher. The seronegative patients had better outcome than the other two groups.